Tag
The Essence-TIMI 73b trial reveals that despite a 64% reduction in triglycerides and a 72% drop in remnant cholesterol via olezarsen, non-calcified coronary plaque volume remained unchanged over 12 months.
This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefinin
A massive cohort study of 245,388 US adults reveals that 1 in 287 carries a familial hypercholesterolemia mutation. Despite high risks for premature heart disease, most carriers remain undertreated, with fewer than 20% of those with establi
